In This Issue  by unknown
Leading Edge
In This IssueReversing Drug Resistance
PAGE 69
Cancer drug efficacy is severely limited by the development of drug resis-
tance. By modeling acquired drug resistance in various human cancer cell
lines, Sharma et al. identify a subpopulation of cells that transiently exhibit
a ‘‘drug-tolerant’’ phenotype associated with a distinct chromatin state
that requires particular chromatin-modifying enzymes. Thus, disrupting drug
tolerance via agents that affect chromatin dynamics may yield a therapeutic
opportunity to prevent the development of drug resistance.Telomeres, Tetraploidy, and Tumorigenesis
PAGE 81
The formation of tetraploid cells is thought to be an early step in the generation of aneuploid human cancers. In this
issue, Davoli et al. report that tetraploidization can be induced by telomere dysfunction. They show that the persistent
DNA damage signal elicited by dysfunctional telomeres leads to bypass of mitosis and entry into a second S phase in
cells that lack p53. Telomere attrition is common in human cancer, and thus this tetraploidization mechanism presents
a likely route to tumor aneuploidy in humans.Avoiding Entanglements in Meiosis
PAGE 94
Chromosome pairing is a central issue for meiosis: it involves not only recognition of homology but also juxtaposition
of entire chromosomes. Storlazzi et al. now show that three recombination proteins play direct roles in pairing before
their known effects on recombination. In addition, these factors also play defined roles in avoiding entanglement
of paired homologs. Together, these results provide the first molecular insights into meiotic pairing and interlock
resolution.Bacteria Announce Braking News
PAGE 107
Bacteria swim by means of rotating flagella. Motile bacteria can follow
chemical gradients and control the direction of their movement with the
help of sensory machinery. Here Boehm et al. show that bacteria can
also adjust their swimming velocity in response to changing environmental
conditions, like the depletion of nutrients. Swimming velocity is controlled
by the synergistic action of at least five signaling proteins that adjust the
cellular concentration of cyclic di-GMP.Cell 141, April 2, 2010 ª2010 Elsevier Inc. 1
Cat Got Your Juxtamembrane Domain?
PAGE 117
p120 catenin (p120) helps retain adhesion complexes at the cell surface by
binding directly to cadherin’s cytoplasmic juxtamembrane domain (JMD).
Ishiyama et al. combine structural and functional approaches to reveal that
p120 stabilizes E-cadherin by protecting an endocytic motif within the JMD
through two distinct interfaces. These results provide insights into the signifi-
cance of p120-regulated stability of cadherin-catenin complexes in both adhe-
rens junction formation and neuronal synapse development.SettingaNewPARforRNPBindingSite Identification
PAGE 129RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs)
and microRNA-containing ribonucleoproteins (miRNPs). In this issue, Hafner et al. report PAR-CLIP, a method to
determine transcriptome-wide binding sites of RBPs and miRNPs that is based on in vivo crosslinking of nucleo-
side-analog-labeled RNA. The crosslinking positions between RNA and RBP are pin-pointed by characteristic
sequence transitions in the cDNA prepared from crosslinked RNA. PAR-CLIP presents a resource for the precise
identification of RNP binding sites.I&Drosophila
PAGE 142
Heart disease is the most common cause of morbidity and mortality in humans. Using a genome-wide RNAi screen in
Drosophila, Neely et al. identify 800 candidate genes involved in cardiac development and function. Among them is
Not3, part of the CCR4-Not complex implicated in transcriptional regulation. Fly and mouse hearts with reduced
Not3 function exhibit poor contraction and heart failure. Humans with NOT3 SNPs also exhibit electrophysiological
abnormalities. The findings demonstrate the utility of fly RNAi screens in identifying regulators of mammalian heart
function.Optogenetics Dons Night Goggles
PAGE 154
Optogenetic technologies employ microbial opsins and light pulses to control
biological processes within targeted cells in vivo with high temporal precision.
Here Gradinaru et al. describe the next generation of optogenetic tools, which
enable targeting of cells for optical control solely by virtue of their topological
and connectivity relationships within tissue. Furthermore, the authors extend
the reach of optogenetic control across the entire visible spectrum up to the
infrared border. These results open the door for precise examination of intact
neural circuits.Targeting Placental Growth Factor in Cancer
Revisited
PAGE 166 and PAGE 178
Treatmentwith an anti-placenta growth factor (PlGF) antibody hadbeen previously reported byCarmeliet and colleagues
to inhibit angiogenesis and primary tumor growth. Bais et al. now report that PlGF neutralization or genetic ablation of the
tyrosine kinase domain of the PlGF receptor, VEGFR-1, did not result in tumor growth inhibition. Their data argue against
an important role of PlGF during primary tumor growth and suggest re-evaluation of the clinical potential of anti-PlGF
antibodies. Carmeliet and colleagues (Van de Veire et al.) provide new pharmacological and genetic data to further
support the merits of targeting PlGF in anticancer therapies.Cell 141, April 2, 2010 ª2010 Elsevier Inc. 3
